BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
BioRestorative Therapies, Inc. (BRTX) is a Biotechnology company based in US with a market capitalization of $4.6M. Revenue declined 10.3% year-over-year and free cash flow was negative at -$10.9M. This page tracks BRTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 11 employees · IPO Dec 5, 2012
Valuation
Valuation & price
$0.19as of May 17, 2026· -89.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
12.88
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$4.6M
Market cap
-10.3%
Revenue growth (YoY)
93.4%
Gross margin
-$10.9M
Free cash flow (USD)
-$3M
Net debt
Net cash position
15.8%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-0.19)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 16, 2026Filing
Executive Resignations and Appointments
- 8-K eventJun 12, 2026Filing
Revolving Credit Agreement
- 8-K eventJun 12, 2026Filing
Executive Employment Agreement
- 8-K eventMay 29, 2026Filing
Executive Employment Agreement
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventMay 1, 2026Filing
Executive Bonuses Approved
- 8-K eventApr 23, 2026Filing
Corporate Presentation Update
Questions
Frequently asked questions
What is BioRestorative Therapies, Inc.'s market cap?
BioRestorative Therapies, Inc. (BRTX) has a market capitalization of $4.6M.
What is BRTX's P/E ratio?
A meaningful P/E ratio is not available for BRTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is BRTX's price-to-book (P/B) ratio?
BRTX trades at 12.88 times book value per share.
When did BioRestorative Therapies, Inc. last report earnings?
BRTX last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying BRTX stock?
SEC Form 4 filings show no open-market insider buys at BioRestorative Therapies, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.